- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 7: Guidelines for Diagnostic Test Use
The panelists discuss guidelines for diagnostic test use and the biggest challenge from a payer standpoint.
Francisco J. Esteva, MD, PhD, and Daniel F. Hayes, MD, discuss guidelines for diagnostic test use from the National Comprehensive Cancer Network and the American Society of Clinical Oncology and the differences in how each organization approached the development of guidelines.
John L. Fox, MD, added that the biggest challenges with guidelines are the underuse and overuse of diagnostics—the former being a larger issue than the latter. From a payer vantage, tests that are well validated and have clinical utility should be done and they are willing to pay because the high cost of patients receiving an inappropriate therapy is an avoidable expense.
“So we’re encouraging testing and making sure that patients are appropriate for therapy,” he said.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
ACA Dependent Coverage Extension and Young Adults’ Substance-Associated ED Visits
September 15th 2025This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.
Read More
